Methodological proposal to explore and design future health innovation policies and opportunities for Responsible Research and Innovation (RRI)

Arturo Argüello¹, Alicia Ortega-Rodríguez¹ and Pablo Álvarez^{2,3}.

¹Oficina de Transferencia de Tecnología del Sistema Sanitario Público de Andalucía. Fundación Pública Andaluza Progreso y Salud

²Instituto de Investigación Biosanitaria ibs.GRANADA

³Fundación para la Investigación Biosanitaria de Andalucía Oriental: FIBAO

Abstract

Responsible Research and Innovation (RRI) seeks to align the research results with the needs of society to respond to current and future problems, also encompassing financial instruments, innovative public policies, and the distribution of resources. These policies should prioritize research in those areas with the greatest impact on society, and particularly in health research, this impact should be focused on responding to clinical problems of the population rather than economic impact. A methodology is proposed that uses information from open sources to identify discrepancies between the results of the most translational research of a region and its health needs, in order to provide useful information for the formulation of innovation policies.

Key Words

Health Innovation

Patents

Responsible Research and Innovation

Health Research Policies

Introduction

Responsible Research and Innovation (RRI) was promoted by the European Commission in November 2014 through the Rome Declaration on RRI, calling on member states and their organizations and institutions to focus and prioritize RRI, declaring it essential for sustainable innovation and highlighting the responsibility of scientific achievement to be able to meet the needs and expectations of society. The statement also included the need to search for methodologies to design future innovation policies¹.

Since the middle of the last century, patents have been used as a source of information for evaluating science and technology activities, and its use has increased as data has become more accessible electronically². However, such information is imperfect (for example, not all innovations or inventions are patented), and its limitations should be considered when using it to formulate R&D&I policies, so it should preferably be combined with other indicators³.

In the biomedical field, the clinical application of most technologies requires substantial investment in research and development, so the use of industrial property rights, including patents, usually accompanies the development of these technologies from the earliest stages to reduce the risk of not maximizing the investment. This makes patents in this field especially useful for the identification of new technologies and technological changes, the analysis of technological trends, the analysis and monitoring of competitors, and the support for decision making in the planning and management of R&D&I^{4,5}.

The information contained in clinical trials is frequently used for competitive intelligence analysis in the pharmaceutical field, together with market and patent information⁶, and it is also used for reviews. Since the promulgation of the Helsinki declaration in 1964, and also promoted by the editors of scientific journals⁷, the different countries have made the registration of information from human clinical trials mandatory by law. The WHO established a minimum number of data to be recorded⁸, which constitutes an open source of information that can be used for technological intelligence.

The International Classification of Diseases (ICD) established by the WHO⁹, allows the standardization for reporting diseases and health conditions, facilitating the comparison of mortality and morbidity statistics worldwide.

In this work we describe a methodology for obtaining information that will allow the definition of future health innovation policies, for the identification of research opportunities and prioritization of R&D&I funding through the prioritization of the projects that best suit the biomedical technologies of interest detected.

Methods

For the analysis, we used cause-of-death and hospital morbidity per 100.000 population 2018 statistical data, classified in accordance with the International Classification of Diseases, 10th Revision (ICD-10), and extracted from the National Institute of Statistics (INE).

The patent search was performed according to the International Patent Classification (IPC), defining the appropriate classes for each ICD-10. The search was carried out in Global Patent Index (GPI) (<https://www.epo.org/searching-for-patents/technical/espacenet/gpi.html>), and the period analyzed was from January 1, 2009 to December 31, 2019. Patents filed by residents of Andalusia were searched in Invenes (https://www.oepm.es/es/Bases_de_Datos_Invenciones.html), using the same classification.

The clinical trial data for each therapeutic area, related to each geographical area - Andalusia, Spain and worldwide - and for the dates established in the study were obtained from the following registries: <http://www.anzctr.org.au/> (Australia); <http://www.chictr.org/> (China); <http://www.clinicaltrials.gov> (USA); <https://www.clinicaltrialsregister.eu> (EU); <http://ctri.nic.in> (India); <http://www.germanctr.de> (Germany); <http://www.ensaiosclinicos.gov.br> (Brazil); <http://www.irct.ir> (Iran); <http://isrctn.org> (United Kingdom); <http://registroclinico.sld.cu> (Cuba); <http://www.umin.ac.jp/ctr/index/htm> (Japan); <http://www.trialregister.nl/trialreg/index.asp> (The Netherlands).

The results obtained are shown in Table 1 and have been represented as percentages of the total analyzed in Figure 1. The data from the study can be consulted at (Reserved DOI: 10.17632/m3gtm59vfg.1).

Results

Figure 1 shows that circulatory diseases are the main cause of mortality and morbidity in Spain; however, the number of patents and clinical trials, indicators of investment in this area, is not equivalent. In neoplasms, the second leading cause of death, a correlation is observed. In diseases of the digestive system, genitourinary system and respiratory system, there is a deviation between morbidity and the clinical trials registered. With respect to skin, endocrine and nervous system diseases, a greater inversion is observed, that is not in accordance with the mortality and morbidity data.

Discussion

The same methodology could be applied at a more specific level, for example, to determine the R&D&I situation in specific diseases that are particularly prevalent in a region.

Specific developments and mechanisms have been generated to include in the research and innovation process the social utility of science and its potential impacts, enabling greater assurance of translational research. Currently, RRI is a topic that involves researchers, companies, scientific institutions, and research funding agencies. It is therefore proposed to use the term collective responsibility¹⁰ to define this concept and to implement the positive impacts of research and innovation.

The collection, correlation and processing of publicly accessible data such as patents and clinical trials can be used to obtain useful information^{11,12}, particularly in the formulation of regional innovation policies^{13,14}. By adding ICD statistics, it is possible to identify technological fields where, for reasons of public health, it may be interesting to prioritize research funding from the public sector, so that public research and innovation have an impact on clinical care, fostering a culture of RRI in the scientific community and facilitating the transfer of scientific achievements to society.

References

1. Investigación e Innovación Responsable aspiran a ampliar la participación de la sociedad. Available in https://ec.europa.eu/environment/ecoap/about-eco-innovation/policies-matters/eu/responsible-research-and-innovation-push-seeks-to-broaden-societal-involvement_es [consulted 06/03/2021].
2. OCDE, *Manual de estadísticas de patentes de la OCDE*, Publicaciones de la OCDE, París, 2009. Available in <https://doi.org/10.1787/9789264056442-en> [consulted 06/03/2021].
3. OECD (2015), *Frascati Manual 2015: Guidelines for Collecting and Reporting Data on Research and Experimental Development*, The Measurement of Scientific, Technological and Innovation Activities, OECD Publishing, Paris, <https://doi.org/10.1787/9789264239012-en>.
4. Basberg BL. Patents and the measurement of technological change: A survey of the literature. *Research Policy* 1987,16, 2–4: 131–141
5. Ernst H. The use of patent data for technological forecasting: The diffusion of CNC-technology in the machine tool industry. *Small Business Economics* 1997, 9, 4: 361–381.
6. Aspinall Y. Competitive intelligence in the biopharmaceutical industry: The key elements. *Business Information Review*, 2011, 28, 101-104
7. De Angelis C, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. *N Engl J Med* 2004;351:1250-1
8. Sim I, Chan AW, Gülmezoglu AM, Evans T, Pang T. Clinical trial registration: transparency is the watchword. *Lancet* 2006;367:1631-3
9. WHO. Classifications. International Classification of Diseases (ICD). Available in <https://www.who.int/classifications/classification-of-diseases#> [consulted 06/03/2021].
10. Jakobsen SE, Fløysand A, Overton J. Expanding the field of Responsible Research and Innovation (RRI)—from responsible research to responsible innovation. 2019. *Eur Plann Stud*, 27:12, 2329-43
11. Álvarez P, Reyes M, Sánchez-Cantalejo J, Argüello A. Analysis of factors associated with Grant for PCT national phase entries patent: a mathematical model. *Eur J Anat*, 2019. 23(5), 333-340.

12. Doello K, Ortiz R, Álvarez PJ, Melguizo C, Cabeza L, Prados J. Latest in vitro and in vivo assay, clinical trials and patents in cancer treatment using curcumin: a literature review. *Nutr Canc*, 2018. 70(4), 569-578.
13. Argüello A. et al. Análisis de patentes y desarrollo territorial: Ejemplo en el ámbito Biosanitario. *Journal of Economic & Business Intelligence*, 2020, 2(2):13 – 9.
14. Argüello A, Oruezabal RI, Álvarez P. Las unidades de inteligencia competitiva y prospectiva como motor director de la innovación tecnológica en los sistemas sanitarios, 2021 *Journal of Economic & Business Intelligence*, 3(5):43 – 9.

Authorship contributions

A. Argüello, A. Ortega-Rodríguez and P. Álvarez conceived the study. A. Ortega-Rodríguez carried out the searches in the databases. All authors contributed ideas, reviewed the drafts, and approved the final version.

Financing

This work has been carried out with the help AT-6052, entitled "*Prospección de Campos Tecnológicos en Biomedicina mediante el Análisis Estratégico de Patentes*", funded by the Consejería de Economía, Conocimiento, Empresas y Universidad and co-financed by the European Regional Development Fund (ERDF).

Conflicts of interest

None.

Arturo Argüello ORCID <https://orcid.org/0000-0002-0622-4801>

Alicia Ortega-Rodriguez ORCID <https://orcid.org/0000-0001-7469-6723>

Pablo Álvarez ORCID <https://orcid.org/0000-0001-6405-8066>

Table 1. Raw data extracted from INE databases, GobaI Patent Index and clinical trial registries for each ICD-10. In parentheses, percentage with respect to the total for each column.

ICD-10	Andalusia mortality	Andalusia morbidity*	Spain mortality	Spain morbidity*	Andalusia patents	Spain patents	World patents	Andalusia CTs	Spain CTs	World CTs
Infectious	1176	208	6398	245	43	414	97566	345	923	19810
	(1,7%)	(3,5%)	(1,6%)	(3,2%)	(9,9%)	(12,2%)	(12,2%)	(10,0%)	(10,5%)	(10,5%)
Tumors	18261	832	112714	991	82	584	107451	1400	3099	43114
	(27,2%)	(14,1%)	(28,2%)	(13,0%)	(18,9%)	(17,2%)	(13,4%)	(40,6%)	(35,3%)	(22,9%)
Blood	297	76	1946	92	18	297	73034	125	362	6196
	(0,4%)	(1,3%)	(0,5%)	(1,2%)	(4,1%)	(8,7%)	(9,1%)	(3,6%)	(4,1%)	(3,3%)
Endocrine	2268	145	13465	188	32	284	62163	299	697	19675
	(3,4%)	(2,5%)	(3,4%)	(2,5%)	(7,4%)	(8,4%)	(7,8%)	(8,7%)	(7,9%)	(10,4%)
Mental disorders	2447	151	22376	253	11	120	15186	49	213	9343
	(3,6%)	(2,6%)	(5,6%)	(3,3%)	(2,5%)	(3,5%)	(1,9%)	(1,4%)	(2,4%)	(5,0%)
Nervous System	4221	186	26279	259	93	491	71864	338	966	29147
	(6,2%)	(3,2%)	(6,6%)	(3,4%)	(21,4%)	(14,4%)	9,0%)	(9,8%)	(11,0%)	(15,5%)
Circulatory	22706	1102	120859	1310	40	251	61356	268	763	17684
	(33,7%)	(18,7%)	(30,2%)	(17,1%)	(9,2%)	(7,4%)	(7,7%)	(7,8%)	(8,7%)	(9,4%)
Respiratory	8375	888	53687	1359	7	152	45427	163	449	9618
	(12,5%)	(15,1%)	(13,4%)	(17,8%)	(1,6%)	(4,5%)	(5,7%)	(4,7%)	(5,1%)	(5,1%)
Digestive	4028	1097	21689	1306	20	167	88448	183	516	13251
	(6,0%)	(18,7%)	(5,4%)	(17,1%)	(4,6%)	(4,9%)	(11,1%)	(5,3%)	(5,9%)	(7,0%)
Skin	304	87	1826	119	56	300	72556	51	164	6456
	(0,4%)	(1,5%)	(0,5%)	(1,6%)	(12,9%)	(8,8%)	(9,1%)	(1,5%)	(1,9%)	(3,4%)
Osteomuscular	882	536	5205	768	19	206	49943	148	392	8001
	(1,3%)	(9,1%)	(1,3%)	(10,1%)	(4,4%)	(6,1%)	(6,2%)	(4,3%)	(4,5%)	(4,2%)
Genitourinary	2360	574	13941	750	13	134	54148	83	231	6175
	(3,5%)	(9,8%)	(3,5%)	(9,8%)	(3,0%)	(3,9%)	(6,8%)	(2,4%)	(2,6%)	(3,3%)

* Hospital Morbidity Rates per 100.000 inhabitants.

Figure 1. Graphical representation of the percentages of each variable proportional to the area of each circle for each ICD-10.